{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"45.1","upperLimit":"79.6","value":"63.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"33"}],"units":"Participants"}],"description":"Response is defined as corrected serum calcium (CSC) ≤ 11.5 mg/dL, within 10 days after the first dose of denosumab. For all CSC values, if albumin was \\< 4 g/dL, the following formula was used to calculate CSC: CSC = Total serum calcium \\[mg/dL\\] + (0.8 x (4 - serum albumin \\[g/dL\\]))","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received denosumab at a dose of 120 mg subcutaneously (SC) every 4 weeks (Q4W) with a loading dose of 120 mg SC on study Days 8 and 15.","id":"OG000","title":"Denosumab"}],"paramType":"NUMBER","populationDescription":"Response Analysis Subset including all participants who received at least 1 dose of denosumab and had a screening CSC (from local lab) \\> 12.5 mg/dL (3.1 mmol/L).","reportingStatus":"POSTED","timeFrame":"10 days","title":"Percentage of Participants With a Response Within 10 Days of First Dose of Denosumab","type":"PRIMARY","unitOfMeasure":"percentage of participants"}